Home > Resources > Whitepapers > Valorization of Starch to Biobased Materials

Cell and Gene Therapy

Valorization of Starch to Biobased Materials

May 30, 2022

Valorization of

Many concerns are being expressed about the biodegradability, biocompatibility, and longterm viability of polymer-based substances. This prompted the quest for an alternative source of material that could be utilized for various purposes.

Spotlight

St. David's HealthCare

With more than 110 sites across Central Texas, St. David’s HealthCare includes seven of the area’s leading hospitals and is one of the largest health systems in Texas. The organization was recognized with a Malcolm Baldrige National Quality Award—the nation’s highest presidential honor for performance excellence in 2014. St. David’s HealthCare is the third-largest private employer in the Austin area, with more than 9,000 employees.

OTHER WHITEPAPERS

T Cell Expansion in Small Scale Bioreactors

whitePaper | October 28, 2022

Adoptive cell therapy (ACT), a branch of immunotherapy, offers a promising treatment for chronic viral infections and malignant diseases such as cancer [1]. This innovative approach involves the autologous or allogenic transplant of immune cells into the patient’s body.

Read More

U.S. NATIONAL SCIENCE FOUNDATION

whitePaper | August 21, 2022

The “Government Performance and Results Act” and the “GPRA Modernization Act of 2010 require federal agencies to develop strategic plans setting forth long-term goals and objectives. Guidance.

Read More

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Read More

The affordability hurdle for gene therapies

whitePaper | October 12, 2022

Advanced therapy medicinal products cell and gene therapies offer tremendous hope for patients either by actually curing serious diseases or by alleviating suffering.

Read More

HFPP Fraud, Waste, and Abuse in the Context of COVID-19

whitePaper | January 24, 2022

Since early 2020, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome.

Read More

BIOPHARMACEUTICAL INDUSTRY AND INTERRELATED BIOTECHNOLOGY ORGANIZATIONS

whitePaper | November 21, 2019

Our Accounting and Finance team has published an overview of the accounting and finance challenges facing the Biopharmaceutical industry and interrelated Biotechnology organizations.

Read More

T Cell Expansion in Small Scale Bioreactors

whitePaper | October 28, 2022

Adoptive cell therapy (ACT), a branch of immunotherapy, offers a promising treatment for chronic viral infections and malignant diseases such as cancer [1]. This innovative approach involves the autologous or allogenic transplant of immune cells into the patient’s body.

Read More

U.S. NATIONAL SCIENCE FOUNDATION

whitePaper | August 21, 2022

The “Government Performance and Results Act” and the “GPRA Modernization Act of 2010 require federal agencies to develop strategic plans setting forth long-term goals and objectives. Guidance.

Read More

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Read More

The affordability hurdle for gene therapies

whitePaper | October 12, 2022

Advanced therapy medicinal products cell and gene therapies offer tremendous hope for patients either by actually curing serious diseases or by alleviating suffering.

Read More

HFPP Fraud, Waste, and Abuse in the Context of COVID-19

whitePaper | January 24, 2022

Since early 2020, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome.

Read More

BIOPHARMACEUTICAL INDUSTRY AND INTERRELATED BIOTECHNOLOGY ORGANIZATIONS

whitePaper | November 21, 2019

Our Accounting and Finance team has published an overview of the accounting and finance challenges facing the Biopharmaceutical industry and interrelated Biotechnology organizations.

Read More

More Whitepapers

Spotlight

St. David's HealthCare

With more than 110 sites across Central Texas, St. David’s HealthCare includes seven of the area’s leading hospitals and is one of the largest health systems in Texas. The organization was recognized with a Malcolm Baldrige National Quality Award—the nation’s highest presidential honor for performance excellence in 2014. St. David’s HealthCare is the third-largest private employer in the Austin area, with more than 9,000 employees.

Events